AbCellera Biologics (ABCL) Interest & Investment Income (2022 - 2026)

AbCellera Biologics (ABCL) has 5 years of Interest & Investment Income data on file, last reported at $3.6 million in Q1 2026.

• Quarterly Interest & Investment Income fell 34.04% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.9 million (down 28.8% YoY) and the FY2025 annual result came in at $28.3 million, down 26.37% from the prior year.
• Interest & Investment Income retreated to $3.6 million in Q1 2026, from $5.9 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $11.0 million in Q4 2023 to a low of $665000.0 in Q1 2022.
• A 5-year average of $7.4 million and a median of $8.5 million in 2022 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 1367.52% — and 2025, when it slumped 46.9%.
• Tracing ABCL's Interest & Investment Income over 5 years: stood at $8.5 million in 2022, then grew by 29.5% to $11.0 million in 2023, then fell by 20.98% to $8.7 million in 2024, then slumped by 31.7% to $5.9 million in 2025, then plunged by 38.46% to $3.6 million in 2026.
• The last three Interest & Investment Income figures came in at $3.6 million (Q1 2026), $5.9 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.